Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.
about
Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.CT-P13: design, development, and place in therapySwitching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician.A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe.Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product.Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis.CT-P13 in the treatment of rheumatoid arthritis.Tumor necrosis factor inhibitors in psoriatic arthritis.Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer.Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.Biosimilars for psoriasis: clinical studies to determine similarity.Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.The design of clinical trials to support the switching and alternation of biosimilars.Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.Safety considerations of biosimilarsSwitching from originator biological agents to biosimilars: what is the evidence and what are the issues?Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study.Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry.Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4.Comparative effectiveness of the biosimilar CT-P13.Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence.Serum sickness-like disease after switching to biosimilar infliximab.Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: 52-Week Phase 3 Randomized Study Results.A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis.Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries.ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future.Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin AmericaSwitching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
P2860
Q33726030-1ED89FCC-E697-4B0E-AF1C-E0DCD134070CQ33803728-6AA69009-55E2-4923-BB08-489F0C214DFDQ33840949-E00D2655-B2E0-4BD7-989E-938B5C3F7FB9Q33881234-1D7879CB-145B-4266-999B-9D9827E1E3DAQ37453045-9D6036D7-7183-4C73-9BDA-F969BFE43FCBQ37616966-14E5652C-8EC8-413D-9FE8-9488F2FD1AB4Q37698663-299E85F6-A1C7-40CB-93B6-4F47CD889419Q38375767-93FF6AD5-1FEA-46ED-9387-5EC1CB70055DQ38676104-82E3B09F-A58C-488F-B217-05B805F79A28Q38685543-0D26C975-4C02-4AE6-A9E5-B5D05FAA0C45Q38686396-5602077C-8F64-4AB3-B2C8-74AA16FDF8BCQ38708927-9DEB3983-7F5A-4568-BB20-BCA027BC117DQ38957406-FC2204D0-9ED3-4F5F-9A03-E4B46738759EQ38960108-180A0ABF-A9E3-4E0A-8B67-985956EE3D91Q38963970-68E2F883-E6C5-429B-840D-4A7CC8C7B4E2Q39016810-20A25414-4B0C-4E96-8F21-A749A76C558CQ39051341-D79386D8-CF56-4F10-A363-5023B418555CQ42353230-3D1A44A3-7BE9-42F5-A775-6ADC7B0AA4A3Q42360803-74D3B45A-3BC6-4BF5-A3E4-A331C5B6B573Q42370959-0014054D-9C7C-4187-B025-EDAA556190ACQ42701889-EC1A9F59-2F8F-461B-8AEF-7474A09B82EFQ44104600-8081CCDC-929E-40B2-8E55-16C288597368Q47095910-E1901042-39A9-43D2-9B72-C1935FC24447Q47418286-94A7AA1F-8D17-45D3-A393-4403CBBB0113Q47656264-20326573-1877-4010-AC4D-E56E997C850FQ47688424-2DA8B1D3-26CD-4E3A-BC4D-4436D6F8A924Q47807650-0087A7D0-C323-4FFE-A43E-C2A3B61A1A2AQ48216426-31F5869F-3041-4ADC-9C74-B1B3EED8010CQ49608190-83038DB0-D280-4F9E-B5D4-1558E30D3761Q49979586-2BF0C356-4D87-49C6-8748-8A3B8400DD89Q50034734-1601984A-4BDD-4E0F-8CCB-23245991E7FDQ50073683-311485FD-B02E-4782-95A4-02674A45774EQ50079741-96C55AC5-05B8-49DF-9D5E-ABE027179C7BQ50083992-BB50153D-4B10-4A9F-8745-49C1CCD26E77Q50108062-E886919C-CF97-4AC1-9203-0E8D13269FD9Q51280643-A5B4C857-0759-4CC4-9F41-CC02352033D7Q52651099-D142277D-D143-4EA3-94C9-EDDC9B55D1B2Q55008089-E6810B2D-8CE6-42A6-924A-F65269A90C7CQ57173064-4290E6EA-2586-4813-BDCE-6B9844CE7777Q57816058-3BE7C3CC-5CAB-4B82-923B-F5C630EB2942
P2860
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Efficacy and safety of switchi ...... the PLANETAS extension study.
@ast
Efficacy and safety of switchi ...... the PLANETAS extension study.
@en
type
label
Efficacy and safety of switchi ...... the PLANETAS extension study.
@ast
Efficacy and safety of switchi ...... the PLANETAS extension study.
@en
prefLabel
Efficacy and safety of switchi ...... the PLANETAS extension study.
@ast
Efficacy and safety of switchi ...... the PLANETAS extension study.
@en
P2093
P2860
P1476
Efficacy and safety of switchi ...... the PLANETAS extension study.
@en
P2093
Carlos Abud-Mendoza
Dae Hyun Yoo
Helena Mikazane
Jürgen Braun
Marek Brzosko
Mie-Jin Lim
Pedro Miranda
Piotr Wiland
Sang Joon Lee
P2860
P304
P356
10.1136/ANNRHEUMDIS-2015-208783
P407
P577
2016-04-26T00:00:00Z